VALPOVIB CR 300*SODIUM VALPROATE 200mg. IP + VALPROIC ACID 87mg. IP

Valpovib CR 300 tablets combine sodium valproate and valproic acid to help control complex partial and absence seizures. Main uses: monotherapy and adjunctive therapy of complex partial seizures, occurring alone or with other seizure types; sole and adjunctive therapy of simple absence seizures; sole and adjunctive therapy of complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures.

Common side effects of Valpovib CR 300 Tablet include nausea; vomiting; abdominal pain; hair loss (alopecia); dizziness; drowsiness or sleepiness. Get medical help at once if you notice hepatotoxicity, including liver failure, usually during the first six months of treatment; pancreatitis, including fatal haemorrhagic cases; hyperammonaemia and hyperammonaemic encephalopathy with lethargy, vomiting or change in mental status.

Each Valpovib CR 300 tablet contains Sodium Valproate 200 mg + Valproic Acid 87 mg. The right dose and how long to take it depend on the condition, age and other medicines, so use Valpovib CR 300 Tablet only as your doctor advises.

The MRP of Valpovib CR 300 Tablet is ₹65.62 for a pack of 10 (Alu Strip). For chemists and distributors, the PTR is ₹50 and the PTS is ₹45.

Each Valpovib CR 300 tablet contains Sodium Valproate 200 mg + Valproic Acid 87 mg. It comes in a pack of 10 (Alu Strip).

Both ingredients break down to the valproate ion in the body. The way valproate works has not been fully established; it is thought to act in epilepsy by increasing the concentration of gamma-aminobutyric acid (GABA) in the brain. Sodium valproate and valproic acid contribute the same active ion.

Must not be used by patients with hepatic disease or significant liver dysfunction. Must not be used by patients with known urea cycle disorders. Must not be used by patients with known mitochondrial disorders caused by POLG mutations, or in children under two years suspected of a POLG-related disorder. Must not be used by patients with known hypersensitivity to valproate. Must not be used to treat women with epilepsy who are pregnant, who plan to become pregnant or who are of childbearing potential unless other medicines have failed to give adequate symptom control or are otherwise unacceptable; exposure in pregnancy can cause neural tube defects, other major birth defects, decreased IQ and neurodevelopmental disorders in the child. check with a doctor first: women who are breastfeeding.

Valpovib CR 300 Tablet is a brand of Vibcare Pharma, sold through its Mind division. It is available for PCD pharma franchise and distribution in India; use the Send Enquiry or WhatsApp button on this page to ask about availability and terms.